secwatch.observer — SEC 8-K summary
======================================

Issuer:     Generation Bio Co. (—)
CIK:        0001733294
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0001558370-23-019374
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Generation Bio cuts 40% of workforce, extends cash runway to 2H 2027
--------------------------------------------------------------------

- Workforce reduction of ~40% approved Nov 27; expected cost savings of ~$120M over three years.
- Cash runway extended into second half of 2027 due to reorganization and reduced operational spend.
- CMO Douglas Kerr and CDO Tracy Zimmermann to depart Jan 28, 2024; severance total $0.7M plus accelerated equity.
- Severance and retention costs estimated $7-8M, recognized in Q4 2023 and Q1 2024.
- Company prioritizes ctLNP delivery for extrahepatic cell types and iqDNA platform for hemophilia A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733294/000155837023019374/0001558370-23-019374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733294/000155837023019374/gbio-20231127x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer